Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.

The company scraps nemvaleukin after the latest failure, of Artistry-6.

The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.

While Cogent joins the FGFR party.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

A look at big oncology deals since 2016 suggests that there have been more duds than successes.

But the groups have yet to see any responses with AU-007 and XTX202 respectively.